Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Agensys
company
About
Agensys offers products to treat various tumors as well as prostate, pancreatic and bladder cancers.
- 251 - 500
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $41.30M
- Industries
- Biotechnology,Health Diagnostics,Pharmaceutical
- Founded date
- Jan 1, 1997
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$41.30M
Agensys has raised a total of
$41.30M
in funding over 2 rounds. Their latest funding was raised on
Jul 12, 2007 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 12, 2007 | Series D | $41.30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Agensys is funded by 1 investors.
Innovis Investments
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
